Meeting
2016 ASCO Annual Meeting
Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus <1%).
Authors
Sangeetha Meda Reddy
The University of Texas MD Anderson Cancer Center, Houston, TX
Sangeetha Meda Reddy , Arup Kumar Sinha , Limin Hsu , Carlos Hernando Barcenas , Vicente Valero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 1077)
DOI
10.1200/JCO.2016.34.15_suppl.1077
Abstract #
1077
Poster Bd #
182
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
First Author: Sung Jun Ma
Poster
2021 ASCO Annual Meeting
Association of the presence of estrogen and progesterone receptors in uterine carcinosarcoma with improved survival and increased immunogenicity.
First Author: Nathaniel L. Jones
Poster
2021 ASCO Annual Meeting
Survival following locoregional recurrence in breast cancer by clinical subtype.
First Author: Kirsten Allen
Poster
2016 ASCO Annual Meeting
Optimal weight control strategies in cancer patients: A systematic review.
First Author: Nathalie LeVasseur